Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells

Clinical Immunology

Volumn 120, Issue 1, 2006, Pages 76-90

  Ryan, Elizabeth P ^a   Pollock, Stephen J ^a   Kaur, Kuljeet ^b   Felgar, Raymond E ^a   Bernstein, Steven H ^a   Chiorazzi, Nicholas ^c   Phipps, Richard P ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c North Shore LIJ Health System ^*  (United States)

Author keywords

B Chronic Lymphocytic Leukemia (B CLL); Cyclooxygenase 2; NSAIDs and Cox 2 selective inhibitors; Prostaglandins

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; CAY 10404; CD38 ANTIGEN; CD40 LIGAND; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN HEAVY CHAIN; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE ACTIVATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; PRIORITY JOURNAL; PROGNOSIS; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

B-LYMPHOCYTES; CELL GROWTH PROCESSES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROST; DINOPROSTONE; ENZYME ACTIVATION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOHISTOCHEMISTRY; INDOMETHACIN; ISOXAZOLES; LEUKEMIA, B-CELL, CHRONIC; NITROBENZENES; PYRAZOLES; SULFONAMIDES; SULFONES; THROMBOXANE A2;

EID: 33745181682     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2005.12.012     Document Type: Article

References (49)

1. Armstrong R.A., Matthews J.S., Jones R.L., and Wilson N.H. Characterisation of PGE2 receptors mediating increased vascular permeability in inflammation. Adv. Prostaglandins, Leukotrienes Essent. Fatty Acids 21A (1991) 375-378
2. Sinicrope F.A., and Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev. 23 (2004) 63-75
3. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J., and Koki A.T. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 (2000) 2637-2645
4. Arun B., and Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin. Oncol. 31 (2004) 22-29
5. Koehne C.H., and Dubois R.N. COX-2 inhibition and colorectal cancer. Semin. Oncol. 31 (2004) 12-21
6. Rao C.V., and Reddy B.S. NSAIDs and chemoprevention. Curr. Cancer Drug. Targets 4 (2004) 29-42
7. Graf B.A., Nazarenko D.A., Borrello M.A., Roberts L.J., Morrow J.D., and Phipps R.P. Proinflammatory signals upregulate COX-2 and increase PGE2 production in biphenotypic B/macrophage cells. Ann. N. Y. Acad. Sci. 905 (2000) 294-296
8. Ryan E.P., Pollock S.J., Murant T.I., Bernstein S.H., Felgar R.E., and Phipps R.P. Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J. Immunol. 174 (2005) 2619-2626
9. Bannerji R., and Byrd J.C. Update on the biology of chronic lymphocytic leukemia. Curr. Opin. Oncol. 12 (2000) 22-29
10. Chiorazzi N., Rai K.R., and Ferrarini M. Chronic lymphocytic leukemia. N. Engl. J. Med. 352 (2005) 804-815
11. Messmer B.T., Messmer D., Allen S.L., Kolitz J.E., Kudalkar P., Cesar D., Murphy E.J., Koduru P., Ferrarini M., Zupo S., Cutrona G., Damle R.N., Wasil T., Rai K.R., Hellerstein M.K., and Chiorazzi N. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Invest. 115 (2005) 755-764
12. Pangalis G.A., Vassilakopoulos T.P., Dimopoulou M.N., Siakantaris M.P., Kontopidou F.N., and Angelopoulou M.K. B-chronic lymphocytic leukemia: practical aspects. Hematol. Oncol. 20 (2002) 103-146
13. Phipps R.P., Ryan E., and Bernstein S.H. Inhibition of cyclooxygenase-2: a new targeted therapy for B-cell lymphoma?. Leuk. Res. 28 (2004) 109-111
14. Hazar B., Ergin M., Seyrek E., Erdogan S., Tuncer I., and Hakverdi S. Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leuk. Lymphoma 45 (2004) 1395-1399
15. Wun T., McKnight H., and Tuscano J.M. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk. Res. 28 (2004) 179-190
16. Fais F., Ghiotto F., Hashimoto S., Sellars B., Valetto A., Allen S.L., Schulman P., Vinciguerra V.P., Rai K., Rassenti L.Z., Kipps T.J., Dighiero G., Schroeder Jr. H.W., Ferrarini M., and Chiorazzi N. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J. Clin. Invest. 102 (1998) 1515-1525
17. Tanji N., Kikugawa T., and Yokoyama M. Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 protein expression. Anticancer Res. 20 (2000) 2313-2319
18. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., Buchbinder A., Budman D., Dittmar K., Kolitz J., Lichtman S.M., Schulman P., Vinciguerra V.P., Rai K.R., Ferrarini M., and Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94 (1999) 1840-1847
19. Kehry M.R., and Castle B.E. Regulation of CD40 ligand expression and use of recombinant CD40 ligand for studying B cell growth and differentiation. Semin. Immunol. 6 (1994) 287-294
20. Oscier D.G., Gardiner A.C., Mould S.J., Glide S., Davis Z.A., Ibbotson R.E., Corcoran M.M., Chapman R.M., Thomas P.W., Copplestone J.A., Orchard J.A., and Hamblin T.J. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100 (2002) 1177-1184
21. Ghia P., Guida G., Stella S., Gottardi D., Geuna M., Strola G., Scielzo C., and Caligaris-Cappio F. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 101 (2003) 1262-1269
22. Mainou-Fowler T., Dignum H.M., Proctor S.J., and Summerfield G.P. The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). Leuk. Lymphoma 45 (2004) 455-462
23. Thornton P.D., Fernandez C., Giustolisi G.M., Morilla R., Atkinson S., A'Hern R.P., Matutes E., and Catovsky D. CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol. J. 5 (2004) 145-151
24. Gentile M., Mauro F.R., Calabrese E., De Propris M.S., Giammartini E., Mancini F., Milani M.L., Guarini A., and Foa R. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br. J. Haematol. 130 (2005) 549-557
25. Farrajota K., Cheng S., Martel-Pelletier J., Afif H., Pelletier J.P., Li X., Ranger P., and Fahmi H. Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism. Arthritis Rheum. 52 (2005) 94-104
26. Yucel-Lindberg T., Ahola H., Nilsson S., Carlstedt-Duke J., and Modeer T. Interleukin-1 beta induces expression of cyclooxygenase-2 mRNA in human gingival fibroblasts. Inflammation 19 (1995) 549-560
27. van der Pouw Kraan T.C., Boeije L.C., Smeenk R.J., Wijdenes J., and Aarden L.A. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181 (1995) 775-779
28. Vezza R., Mezzasoma A.M., Venditti G., and Gresele P. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Thromb. Haemost. 87 (2002) 114-121
29. Damle R.N., Ghiotto F., Valetto A., Albesiano E., Fais F., Yan X.J., Sison C.P., Allen S.L., Kolitz J., Schulman P., Vinciguerra V.P., Budde P., Frey J., Rai K.R., Ferrarini M., and Chiorazzi N. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 99 (2002) 4087-4093
30. Ranger G.S., Thomas V., Jewell A., and Mokbel K. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res. 24 (2004) 2349-2351
31. Shirahama T., Arima J., Akiba S., and Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 92 (2001) 188-193
32. Walker W., and Rotondo D. Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-gamma synthesis. Immunology 111 (2004) 298-305
33. Wittmann M., Larsson V.A., Schmidt P., Begemann G., Kapp A., and Werfel T. Suppression of interleukin-12 production by human monocytes after preincubation with lipopolysaccharide. Blood 94 (1999) 1717-1726
34. Wagenaar-Miller R.A., Hanley G., Shattuck-Brandt R., DuBois R.N., Bell R.L., Matrisian L.M., and Morgan D.W. Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br. J. Cancer 88 (2003) 1445-1452
35. Mitsuhashi M., Tanaka A., Fujisawa C., Kawamoto K., Itakura A., Takaku M., Hironaka T., Sawada S., and Matsuda H. Necessity of thromboxane A2 for initiation of platelet-mediated contact sensitivity: dual activation of platelets and vascular endothelial cells. J. Immunol. 166 (2001) 617-623
36. Boccaccio C., Sabatino G., Medico E., Girolami F., Follenzi A., Reato G., Sottile A., Naldini L., and Comoglio P.M. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 434 (2005) 396-400
37. Capone M.L., Tacconelli S., Sciulli M.G., and Patrignani P. Clinical pharmacology of selective COX-2 inhibitors. Int. J. Immunopathol. Pharmacol. 16 (2003) 49-58
38. Fung H.B., and Kirschenbaum H.L. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Clin. Ther. 21 (1999) 1131-1157
39. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L., and Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 12013-12017
40. Cuni S., Perez-Aciego P., Perez-Chacon G., Vargas J.A., Sanchez A., Martin-Saavedra F.M., Ballester S., Garcia-Marco J., Jorda J., and Durantez A. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18 (2004) 1391-1400
41. Furman R.R., Asgary Z., Mascarenhas J.O., Liou H.C., and Schattner E.J. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J. Immunol. 164 (2000) 2200-2206
42. Romano M.F., Lamberti A., Tassone P., Alfinito F., Costantini S., Chiurazzi F., Defrance T., Bonelli P., Tuccillo F., Turco M.C., and Venuta S. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 92 (1998) 990-995
43. Brown J.R., and DuBois R.N. Cyclooxygenase as a target in lung cancer. Clin. Cancer Res. 10 (2004) 4266s-4269s
44. DeLong P., Tanaka T., Kruklitis R., Henry A.C., Kapoor V., Kaiser L.R., Sterman D.H., and Albelda S.M. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res. 63 (2003) 7845-7852
45. Mann J.R., and DuBois R.N. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J. 10 (2004) 145-152
46. Bellosillo B., Pique M., Barragan M., Castano E., Villamor N., Colomer D., Montserrat E., Pons G., and Gil J. Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 92 (1998) 1406-1414
47. Patel M.I., Subbaramaiah K., Du B., Chang M., Yang P., Newman R.A., Cordon-Cardo C., Thaler H.T., and Dannenberg A.J. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin. Cancer Res. 11 (2005) 1999-2007
48. Jendrossek V., Handrick R., and Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J. 17 (2003) 1547-1549
49. El-Rayes B.F., Ali S., Sarkar F.H., and Philip P.A. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol. Cancer Ther. 3 (2004) 1421-1426